117 related articles for article (PubMed ID: 21289364)
1. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab.
Bates M; Sperinde J; Köstler WJ; Ali SM; Leitzel K; Fuchs EM; Paquet A; Lie Y; Sherwood T; Horvat R; Singer CF; Winslow J; Weidler JM; Huang W; Lipton A
Ann Oncol; 2011 Sep; 22(9):2014-2020. PubMed ID: 21289364
[TBL] [Abstract][Full Text] [Related]
2. Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer.
Montemurro F; Prat A; Rossi V; Valabrega G; Sperinde J; Peraldo-Neia C; Donadio M; Galván P; Sapino A; Aglietta M; Baselga J; Scaltriti M
Mol Oncol; 2014 Feb; 8(1):20-6. PubMed ID: 24075779
[TBL] [Abstract][Full Text] [Related]
3. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
4. Very high quantitative tumor HER2 content and outcome in early breast cancer.
Joensuu H; Sperinde J; Leinonen M; Huang W; Weidler J; Bono P; Kataja V; Kokko R; Turpeenniemi-Hujanen T; Jyrkkiö S; Isola J; Kellokumpu-Lehtinen PL; Paquet A; Lie Y; Bates M
Ann Oncol; 2011 Sep; 22(9):2007-2013. PubMed ID: 21285132
[TBL] [Abstract][Full Text] [Related]
5. Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer.
Toi M; Sperinde J; Huang W; Saji S; Winslow J; Jin X; Tan Y; Ohno S; Nakamura S; Iwata H; Masuda N; Aogi K; Morita S; Petropoulos C; Bates M
BMC Cancer; 2010 Feb; 10():56. PubMed ID: 20178580
[TBL] [Abstract][Full Text] [Related]
6. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.
Lipton A; Goodman L; Leitzel K; Cook J; Sperinde J; Haddad M; Köstler WJ; Huang W; Weidler JM; Ali S; Newton A; Fuchs EM; Paquet A; Singer CF; Horvat R; Jin X; Banerjee J; Mukherjee A; Tan Y; Shi Y; Chenna A; Larson J; Lie Y; Sherwood T; Petropoulos CJ; Williams S; Winslow J; Parry G; Bates M
Breast Cancer Res Treat; 2013 Aug; 141(1):43-53. PubMed ID: 23959396
[TBL] [Abstract][Full Text] [Related]
7. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
8. Correlation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapy.
Duchnowska R; Biernat W; Szostakiewicz B; Sperinde J; Piette F; Haddad M; Paquet A; Lie Y; Czartoryska-Arłukowicz B; Wysocki P; Jankowski T; Radecka B; Foszczynska-Kłoda M; Litwiniuk M; Debska S; Weidler J; Huang W; Buyse M; Bates M; Jassem J
Oncologist; 2012; 17(1):26-35. PubMed ID: 22234627
[TBL] [Abstract][Full Text] [Related]
9. Quantitative measurements of tumoral p95HER2 protein expression in metastatic breast cancer patients treated with trastuzumab: independent validation of the p95HER2 clinical cutoff.
Duchnowska R; Sperinde J; Chenna A; Haddad M; Paquet A; Lie Y; Weidler JM; Huang W; Winslow J; Jankowski T; Czartoryska-Arłukowicz B; Wysocki PJ; Foszczyńska-Kłoda M; Radecka B; Litwiniuk MM; Zok J; Wiśniewski M; Zuziak D; Biernat W; Jassem J
Clin Cancer Res; 2014 May; 20(10):2805-13. PubMed ID: 24668646
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V; Nolè F; Redana S; Adamoli L; Martinello R; Aurilio G; Verri E; Sapino A; Viale G; Aglietta M; Montemurro F
Breast; 2014 Feb; 23(1):44-9. PubMed ID: 24210572
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study.
Koutras A; Lazaridis G; Koliou GA; Kouvatseas G; Christodoulou C; Pectasides D; Kotoula V; Batistatou A; Bobos M; Tsolaki E; Papadopoulou K; Pentheroudakis G; Papakostas P; Pervana S; Petraki K; Chrisafi S; Razis E; Psyrri A; Bafaloukos D; Kalogeras KT; Kalofonos HP; Fountzilas G
PLoS One; 2018; 13(12):e0207707. PubMed ID: 30521571
[TBL] [Abstract][Full Text] [Related]
13. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer.
Gogas H; Kotoula V; Alexopoulou Z; Christodoulou C; Kostopoulos I; Bobos M; Raptou G; Charalambous E; Tsolaki E; Xanthakis I; Pentheroudakis G; Koutras A; Bafaloukos D; Papakostas P; Aravantinos G; Psyrri A; Petraki K; Kalogeras KT; Pectasides D; Fountzilas G
J Transl Med; 2016 May; 14(1):136. PubMed ID: 27184134
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
[TBL] [Abstract][Full Text] [Related]
15. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
[TBL] [Abstract][Full Text] [Related]
16. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A
PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015
[TBL] [Abstract][Full Text] [Related]
17. Association between the HER2 Ile655Val polymorphism and response to trastuzumab in women with operable primary breast cancer.
Han X; Diao L; Xu Y; Xue W; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Ann Oncol; 2014 Jun; 25(6):1158-64. PubMed ID: 24608202
[TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
Yardley DA; Kaufman PA; Huang W; Krekow L; Savin M; Lawler WE; Zrada S; Starr A; Einhorn H; Schwartzberg LS; Adams JW; Lie Y; Paquet AC; Sperinde J; Haddad M; Anderson S; Brigino M; Pesano R; Bates MP; Weidler J; Bosserman L
Breast Cancer Res; 2015 Mar; 17(1):41. PubMed ID: 25886996
[TBL] [Abstract][Full Text] [Related]
19. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study.
Montemurro F; Redana S; Nolè F; Donadio M; Jacomuzzzi ME; Valabrega G; Viale G; Sapino A; Aglietta M
BMC Cancer; 2008 Jul; 8():209. PubMed ID: 18652678
[TBL] [Abstract][Full Text] [Related]
20. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer.
Gullo G; Bettio D; Torri V; Masci G; Salvini P; Santoro A
Invest New Drugs; 2009 Apr; 27(2):179-83. PubMed ID: 18663410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
